Pinsent Masons advises Teva Pharmaceuticals on €84m sale of its consumer healthcare brand portfolio to Karo Pharma AB.
16 Feb 2021 | 04:00 pm |
Multinational law firm Pinsent Masons has advised Teva Pharmaceuticals’ subsidiary, Actavis Group PTC, on the successful €84m sale of a suite of consumer healthcare products to Karo Pharma AB (Karo).
The transaction transfers ownership of the brand portfolio, comprised of Flux®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva to Karo. The transactionis is expected to close on April 1.
The Pinsent Masons team was jointly led by partners Allistair Booth and Thilo Schneider and included senior associate Ciaran Wilkinson.
Commenting on the transaction Thilo Schneider said:
"I am so pleased that we have been able to support Teva and to have brought this transaction to a successful conclusion. The sale is significant for both parties and we are proud to have achieved a successful outcome for Teva. We worked closely with them to understand what they wanted to achieve and helped to determine the best options available to them."
Key Contacts
Latest press releases
Show me all press releasesPinsent Masons advises NTR to secure refinancing of Provencialis wind farm (48 MW) in France
Pinsent Masons has advised Irish-based renewables investor and asset manager NTR, acting as sponsor on the successful refinancing of the French wind farm Provencialis, with an installed capacity of 48 MW
Pinsent Masons advises trustee on Videndum DB Pension Scheme transfer to Clara
Multinational law firm Pinsent Masons has advised the Trustee of the Videndum DB Pension Scheme on a bulk transfer of members and assets to Clara, the UK’s only authorised defined benefit pensions superfund.
Pinsent Masons advises Rolls Royce SMR on £599m National Wealth Fund loan facility to accelerate Small Modular Reactor programme
Pinsent Masons has advised Rolls Royce SMR on securing up to £599 million of co-funding facility from the UK’s National Wealth Fund, supporting the generic design development of its Small Modular Reactor (SMR) technology.
People who viewed this press release also viewed
Show me all press releasesPinsent Masons announces FY24/25 results
Multinational law firm Pinsent Masons has today unveiled its unaudited financial results for the year ending 30 April 2025. This year's results have delivered a revenue increase of 4.7% after a year of continued growth within the firm’s core sectors and across its jurisdictions.
Pinsent Masons announces new leadership for Global IP Group and Life Sciences
Pinsent Masons has appointed Judith Krens (Partner, Amsterdam) and Tom Nener (Partner, Birmingham) as co-leads of the Global Intellectual Property (IP) team, and has appointed Charlotte Weekes (Partner, London) as Head of Life Sciences. The appointments come in light of the upcoming departure of Clare Tunstall, the current Head of IP and Life Sciences, who will be leaving the firm in the Autumn.
Pinsent Masons hires senior litigation and investigations partner Melanie Ryan in London
Multinational law firm Pinsent Masons has appointed litigation partner Melanie Ryan to join its Global Investigations team in London.
For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on
Location contacts
Europe: [email protected]
Asia: [email protected]
Middle East: [email protected]
Australia: [email protected]